Hanmi Pharm acquires approval of hypertension/hyperlipidemia treatment
Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kwon) announced on the 17th that ‘Amosartan Q,’ a 3-substance combination drug with 2 antihypertensive substances and 1 anti-hyperlipidemia substance, was approved from the Ministry of Food and Drug Safety(MFDS) as a product.
Amosartan Q, an ETC drug in co...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
